Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Accounts Payables (2020 - 2025)

Historic Accounts Payables for Janux Therapeutics (JANX) over the last 6 years, with Q3 2025 value amounting to $3.4 million.

  • Janux Therapeutics' Accounts Payables rose 3789.6% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.4 million, marking a year-over-year increase of 3789.6%. This contributed to the annual value of $4.0 million for FY2024, which is 6608.91% up from last year.
  • According to the latest figures from Q3 2025, Janux Therapeutics' Accounts Payables is $3.4 million, which was up 3789.6% from $3.5 million recorded in Q2 2025.
  • Janux Therapeutics' Accounts Payables' 5-year high stood at $4.0 million during Q4 2024, with a 5-year trough of $354000.0 in Q2 2021.
  • In the last 5 years, Janux Therapeutics' Accounts Payables had a median value of $2.4 million in 2021 and averaged $2.5 million.
  • In the last 5 years, Janux Therapeutics' Accounts Payables surged by 74745.76% in 2022 and then plummeted by 3633.33% in 2023.
  • Janux Therapeutics' Accounts Payables (Quarter) stood at $2.5 million in 2021, then dropped by 12.16% to $2.2 million in 2022, then grew by 12.27% to $2.4 million in 2023, then skyrocketed by 66.09% to $4.0 million in 2024, then decreased by 15.67% to $3.4 million in 2025.
  • Its Accounts Payables was $3.4 million in Q3 2025, compared to $3.5 million in Q2 2025 and $2.4 million in Q1 2025.